Skip to main content
VRTX logo

VRTX · Vertex Pharmaceuticals Inc

Track VRTX — free
$536.45 +2.25 (+0.42%) At close · Nov 18
Market Cap
$136.01B
Shares
253.54M
Volume · Nov 18 1.29M Avg daily vol (3M) 1.24M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$536.45 Open$532.27 Day$531.38–542.76 52W close$421.03–558.88 Avg vol 30d1.5M Short int4.8M · 1.9% of shares · 3.4d Short vol57% Last earningsNov 2, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 17
Investor event
Povitacicept PDUFA date of November 30th on track, management says

Vertex said its November 30th PDUFA date for povitacicept in IgA nephropathy is on track, with high visibility and confidence. Interim phase three data from the amplitude study of anaxiplin in APOL1-mediated kidney disease are expected early in 2027. Management has talked about $500 million plus in revenue from non-CF products.

5 source passages
we are eagerly awaiting our November 30th PDUFA date for povitacicept in immunoglobulin A nephropathy This looks at anaxiplin in APOL1-mediated kidney disease patients. as you said, we will see it early in 2027 we've talked about $500 million plus in revenue from non-CF products we have high visibility and confidence in our November 30th PDUFA date Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises as Crinetics deal adds costs

Vertex Pharmaceuticals Inc reported Q3 2026 total revenues of $3.4 billion versus $3.1 billion in Q3 2025. The Crinetics Acquisition added compensation and transaction expenses, while cash, cash equivalents and marketable securities fell to $9.8 billion on September 30, 2026.

Revenue $3.44B ▲ 11.8% Net income $653.6M ▼ 39.6% Diluted EPS $2.56 ▼ 39.0%
Read from the MD&A section
3 source passages
In the third quarter of 2026, our total revenues increased to $3.4 billion as compared to $3.1 billion in the third quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas. Our total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $2.2 billion in the third quarter of 2026 as compared to $1.5 billion in the third quarter of 2025, primarily due to approximately $500.0 million of compensation and transaction expenses associated with the Crinetics Acquisition. Our total cash, cash equivalents and marketable securities decreased to $9.8 billion as of September 30, 2026 as compared to $12.3 billion as of December 31, 2025 primarily due to $9.0 billion net cash used to acquire Crinetics and repurchases of our common stock pursuant to our share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan (the “2026 Term Loan”) executed in the third quarter of 2026 and cash flows provided by our operating activities. Open the document at this passage
Nov 2
Earnings call
Third-quarter revenue up 12%; full-year revenue guidance raised

Vertex reported third-quarter total revenue up 12% year-over-year and raised full-year revenue guidance to $13.15 to $13.25 billion, including Krenetics. Non-GAAP operating expense guidance was revised to approximately $6 billion.

4 source passages
Third quarter, total revenue grew 12% year-on-year. we are raising our prior range of $13.1 to $13.2 billion to a revised range of $13.15 to $13.25 billion. The increase reflects the addition of Krenetics, which we expect to contribute $40 to $50 million to full-year 2026 revenue. we are revising our prior combined non-GAAP operating expense guidance of $5.65 to $5.75 billion to a revised estimate of approximately $6 billion. Open the document at this passage
Nov 2
Current report 8-K
Revenue rises 12% as full-year guidance is raised

Vertex Pharmaceuticals reported third quarter 2026 revenue of $3.44 billion, up 12%, and raised full year 2026 revenue guidance to $13.15 billion to $13.25 billion. Povetacicept has an FDA action date of November 30, 2026.

Financial results
4 source passages
BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. Total revenue increased 12% to $3.44 billion compared to the third quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas. Vertex today raised its full year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion to $13.2 billion previously. The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026. Open the document at this passage
Oct 24
Investor event
Investor Event at the American Society of Nephrology Kidney Week 2026

Vertex Pharmaceuticals reported that povitacicept achieved a 52% proteinuria reduction at 36 weeks in IgA nephropathy, with a November 30th PDUFA date, while the fully enrolled Amplitude trial of 522 patients is expected to report interim results early next year.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$12.95B
Trailing 12 months
Net income (TTM)
$3.98B
Trailing 12 months
Revenue growth YoY
+11.8%
Year over year
Operating margin
33.2%
Trailing 12 months
P / E (TTM)
34.5
Trailing earnings · reciprocal yield 2.9%
FCF yield
2.4%
TTM · current market cap
Return on invested capital
18.8%
Trailing 12 months
Net cash
$1.81B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+23.2%
Trailing year
Short interest
1.9%
Latest settlement · 3.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 3, 2026
Q2 FY26

TL;DR. Vertex raised full-year 2026 revenue guidance to $13.1–$13.2 billion on 12% Q2 revenue growth, while CASGEVY surged 78% sequentially with a record pediatric FDA approval and JOURNAVX quadrupled year-over-year on expanding payer coverage.

Bullish
  • + Raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion
  • + CASGEVY Q2 revenue grew 78% sequentially to $76 million with FDA pediatric approval in record 53 days
  • + Povetacicept BLA accepted with November 30 PDUFA, supported by best-in-class Phase 3 RAINIER results
  • + Announced $8.8B Crinetics acquisition adding a fifth pillar in rare endocrine with ~$5B peak sales opportunity
Bearish
  • − Non-GAAP operating expenses now expected at high end of $5.65–$5.75B range due to commercial investment in launches
  • − Gross margin expected to step down in second half due to product mix and manufacturing investments
  • − JOURNAVX gross-to-net normalization delayed to first half of 2027 as PSP utilization exceeds forecast

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg +3%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 84%
mid-range
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +20%
trailing
YTD return +18%
this year
Relative strength +23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $523 › 200d $484 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +149 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.90% of shares out · ▲ +12.9% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,803 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +46%
Y/Y
EPS growth +837%
Y/Y
Free cash flow $3.2B
Valuation P/E 34.5
below peers
Buyback $2.5B
remaining
Balance sheet $5.1B
net cash
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −15%
past year
ATR 2.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Nov 2, 2026
full year 2026
Total revenue Raised $13.15B – $13.25B
Aug 3, 2026 $13.1B – $13.2B changed to Nov 2, 2026 $13.15B – $13.25B
prior FY $12B midpoint +10.0% Y/Y
Revenue from CASGEVY and JOURNAVX combined at least $500M
PALSONIFY revenue $40M – $50M
Combined GAAP R&D, AIPR&D, and SG&A expenses Raised $7.15B – $7.2B
Aug 3, 2026 $6.3B – $6.45B changed to Nov 2, 2026 $7.15B – $7.2B
Combined non-GAAP R&D, AIPR&D, and SG&A expenses Raised $6B
Aug 3, 2026 $5.65B – $5.75B changed to Nov 2, 2026 $6B
Full Year 2026 Financial Guidance
Revenue from PALSONIFY $40M – $50M
Previous outlook earlier release · from the 8-K filed Aug 3, 2026

Still-open targets the latest release did not restate under the same label.

Non-CF product revenue · Full Year 2026 at least $500M
Non-GAAP effective tax rate · Full Year 2026 19.5% – 20.5%
Guided vs delivered · last 5 settled
Total revenue full year 2025
guided $11.9B – $12B
$12B Beat +0.4%
Total product revenues FY 2024
guided $10.55B – $10.75B
$11.02B Beat +3.5%
Product revenues Full Year 2022
guided $8.6B – $8.8B
$8.93B Beat +2.7%
Total product revenues for 2021
guided $7.4B – $7.5B
$7.57B Beat +1.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $523 › 200d $484 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +149 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.90% of shares out · ▲ +12.9% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,803 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $421 Now $536 · 84% Range high $559
vs 200-day avg +11% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
target specialty endocrinologists are prescribing PALSONIFY 500 end of the third quarter of 2026 —
total number of countries where ALYFTREK is reimbursed 32 third quarter of 2026 —
Shares repurchased 1,033,652 the three months ended June 30, 2026 filing —
Non-GAAP diluted net income per share non-GAAP $4.73 Three Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VRTX
Vertex Pharmaceuticals Inc
this stock
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%
ARGX
Argenx SE
$59.19B +11.9% — — 2.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,803
% held
94.2%
Net QoQ
-2.7M sh
Top holder
Capital World Investors
Held Float
View
Held by Funds
Fund positions
1,185
View
Short & Settlement
Short Interest Rising
Shares short
4.8M
Days to cover
3.4d
Change
+548.5K sh
View
Short Volume
Short vol %
57%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$530
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
David J. Taylor
Amount
$1.0K–$15.0K
Traded
Aug 26, 2026
View
Financials
Financials
Revenue (FY)
$12.0B
Net income (FY)
$4.0B
EPS diluted
$15.32
View
Buybacks
Authorized
$4.0B
Remaining
$2.5B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
34

Vertex said its November 30th PDUFA date for povitacicept in IgA nephropathy is on track, with high visibility and confidence. Interim phase three data from the amplitude study of anaxiplin in APOL1-mediated kidney disease are expected early in 2027. Management has talked about $500 million plus in revenue from non-CF products.

View
Proposed Sales
Value
$547.9K
Shares
1.0K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Vertex to Participate in Upcoming…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
VRTX -1.9% +2.3% +19.9% -4.0% +18.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +2.0% +7.8% +23.3% -0.6% +11.3%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$4.00B
Spent (derived)
$1.50B
Remaining
$2.50B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 875320 CUSIP 92532F100 13F (30d) 1626 filings 1520 filers Visit website Investor relations